• Journal of Trauma and Injury
• /
• 제24권2호
• /
• pp.98-104
• /
• 2011

Purpose: The aim of this study was to evaluate the quality of the trauma care system of our hospital, in which emergency physicians care for major trauma patients in the emergency intensive care unit (ICU) in consultation with intervention radiologists and surgeons. Methods: This was a retrospective observational study conducted in an emergency ICU of a tertiary referral hospital. We enrolled consecutive patients who had been admitted to our emergency ICU with major trauma from March 2007 to September 2010. We collected data with respect to demographic findings, mechanisms of injury, the trauma and injury severity score (TRISS), emergency surgery, angiographic intervention, and 6-month mortality. Then, we compared the observed and predicted survivals of the patients. The Hosmer-Lemeshow test and calibration plots by using 10 groups, one for each decile, of predicted mortality were used to evaluate the fitness of TRISS. P-values of greater than 0.05 represent a fair calibration. Results: Among 116 patients, 12 (10.34%) were dead within 6 months after admission to the ICU, and 29 (25.00%) and 38 (32.80%) patients received emergency surgery and angiographic intervention, respectively. The mean injury severity score and revised trauma score were $36.97{\pm}17.73$ and $7.84{\pm}6.75$, respectively. The observed survival and the predicted survival of the TRISS were 89.66% (95% confidence interval [CI]: 84.03~95.28%) and 69.85% (95% CI: 63.80~75.91%), respectively. The calibration plots showed that the observed survival of our patients was consistently higher than the predicted survival of the TRISS ($p$ <0.001). Conclusion: The observed survival for the trauma care system of our hospital, in which emergency physicians care for major trauma patients in the emergency ICU in consultation with intervention radiologists and surgeons, was higher than the predicted survival of the TRISS.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권6호
• /
• pp.2669-2673
• /
• 2012

Purpose: Pancreatic carcinoma is one of the most malignant tumors of the alimentary system, with relatively high incidence rates. The purpose of this study was to assess the efficacy and safety of two regimens for advanced pancreatic carcinoma: continuous transarterial infusion versus systemic venous chemotherapy with gemcitabine and 5-fluorouracil. Methods: Of the 48 patients with advanced pancreatic carcinoma receiving chemotherapy with gemcitabine and 5-fluorouracil, 24 received the selective transarterial infusion, and 24 the systemic chemotherapy. For the continuous transarterial infusion group (experimental group), all patients received gemcitabine 1000 mg/$m^2$, given by 30-minute transarterial infusion, on day 1 of a 4-week cycle for 2 cycles, and a dose of 600 mg/$m^2$ 5-fluorouracil was infused on days 1~5 of a 4-week cycle for 2 cycles. For the systemic venous group (control group), gemcitabine and 5-fluorouracil were infused through a peripheral vein, a dose of 1000 mg/$m^2$ gemcitabine being administrated over 30 min on days 1 and 8 of a 4-week cycle for 2 cycles, and a dose of 600 mg/$m^2$ 5-fluorouracil was infused on days 1~5 of a 4-week cycle for 2 cycles. The effectiveness and safety were evaluated after 2 cyclesaccording to WHO criteria. Results:The objective effective rate in transarterial group was 33.3% versus 25% in the systemic group, the difference not being significant (P=0.626). Clinical benefit rates(CBR) in the transarterial and systemic groups were 83.3% and 58.3%, respectively (P=0.014). The means and medians for survival time in transarterial group were higher than those of the systemic group (P < 0.005). at the same time, the adverse effects did not significantly differ between the two groups (P > 0.05). Conclusion: Continuous transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil could improve clinical benefit rate and survival time of patients with advanced pancreatic carcinoma, compared with systemic venous chemotherapy. Since adverse effects were limited in the transarterial group, the regimen of continuous transarterial infusion chemotherapy can be used more extensively in clinical practice. A CT and MRI conventional sequence can be used for efficacy evaluation after chemotherapy in pancreatic carcinoma.

• 대한방사선기술학회지:방사선기술과학
• /
• 제34권1호
• /
• pp.35-41
• /
• 2011

항암 치료를 받는 환자들은 장기간의 안정적인 정맥확보를 위해 중심정맥 카테터 삽입이 점차 증가하는 추세로 장기간의 항암제 투여, 종합 비경구적 영양법, 반복적 혈액채취와 항생제 투여, 혈액 투석을 위해 시행되고 있다. 그중 주입구를 완전히 피하에 심는 피하매몰형 중심정맥포트(chemo-port)의 설치가 많이 시행되고 있다. 본 연구에서는 항암치료를 받은 환자 중 중재적 방사선과에서 전형적인 카테터 끝이 열려 있는(non-valved) 포트와 새로운 형태의 카테터 끝이 닫혀 있는(valved) 포트를 삽입했던 환자를 대상으로 발생한 합병증이나 문제점에 관한 후향적 조사를 바탕으로 올바른 피하매몰 중심정맥 포트의 선택 및 관리, 해결 방안을 모색하고자 함이다. 2006년 1월부터 2010년 5월까지 피하매몰 중심정맥포트를 삽입한 438명을 대상으로 하였다. 이중 valved 포트를 삽입한 경우는 109명이었고 non-valved 포트를 삽입한 경우는 329명이었다. 포트의 사용상의 문제점을 의뢰한 56명 중 실제로 발생된 30명의 합병증이나 문제점을 valved. non-valved 포트로 나누어 비교 평가하였다. 포트 시술 후 valved 포트에서 문제점과 합병증이 11.93%, non-valved 포트에서 문제점과 합병증이 5.17% 발생하여 상대적으로 valved 포트에서 문제가 더 많이 발생하였다. Valve사용 유무에 따른 포트 사용 시 두께가 얇은 포트의 사용을 권장하고 시술시 환자 감염이 유발하지 않게 가이드라인을 설정해야 하며 시술이후에도 포트를 사용 시 전용바늘을 사용하고 사용 후 생리식염수의 의한 관 세척 등 포트관리에 체계적인 관리가 필요하다. 추가적인 문제점이 발생 시 원인을 찾아내어 해결책을 제시하고 향후 반복적인 합병증이나 문제점이 발생하지 않게 하여 포트 삽입술의 유용성과 안전성을 증대해야 한다.

• 대한방사선기술학회지:방사선기술과학
• /
• 제44권4호
• /
• pp.399-407
• /
• 2021

This study discussed the validity and necessity of compulsory recording of radiographic examination performed by radiological technologist on patients in medical institutions related to radiation exposure. Also, this study provided reasonable evidence of radiographic examination related medical records can contribute to the improvement of public health. Based on overseas cases of implementing a radiographic examination record system, the essential items to be included in medical record are the exposure date, exposure time, exposure method, exposure conditions that is tube voltage, tube current. Name and license number of the radiological technologist who performed the examination should be include in medical record. It is expected that the medical record of the total amount of radiation exposure per year would be in giving the maximum benefit with the minimum exposure to the medical radiation examination of the patient. In addition, interventional radiography medical record should also include exposure time, type and dose of the contrast medium.

• 한국방사선학회논문지
• /
• 제16권7호
• /
• pp.935-942
• /
• 2022

초음파 유도 하 중재적 시술 시 먼저 초음파 장비로 병변의 위치를 파악하며 angio needle을 삽입한다. 이때 실제와 초음파 상 병변의 위치 또는 바늘의 투과 깊이의 차이가 클수록 인체의 주요 혈관이나 조직에 손상을 일으킬 수 있는 위험이 있다. 그러므로 우리는 초음파 장비 업체와 연식에 따라 성능의 차이가 나는지, 이것이 시술의 정확도에 얼마나 영향을 끼치는지 의문이 들어 이를 연구 주제로 삼았다. 본 연구에서는 임의의 초음파 5대의 장비를 사용하여 초음파상 주사침의 길이와 실제 길이를 비교하여 왜곡에 영향을 주는 요인을 분석하고자 하였다. 초음파 유도 하 돼지고기 투과 시 각 연식과 업체가 다른 다섯 대의 초음파 장비로 실제 소시지의 깊이와 바늘의 투과 길이를 영상에서의 값을 측정하여 오차율을 비교하기 위해 spss 22 통계 프로그램의 단일 표본 T 검정을 이용하였다. 그 결과 모두 통계적으로 유의한 범위의 수치가 나왔고, 장비의 연식과 업체만으로 성능을 평가하는 것은 옳지 않다고 판단하였다. 그러므로 초음파 정도 관리를 정기적으로 실시하고 시술자의 숙련도를 높여 실제 시술 부위와 영상에서의 오차율을 줄여야한다고 결론을 내리는 바이다.

• 대한영상의학회지
• /
• 제84권2호
• /
• pp.441-453
• /
• 2023

목적 네 가지 방법으로 토끼의 뇌에 VX2 세포를 이식하여 뇌종양의 생성 유무와 위치, 체적을 분석하고자 한다. 대상과 방법 공여 토끼를 희생하여 얻은 VX2 세포 현탁액을 1) 당일 이식, 2) 냉장 보관 7일 후 이식, 3) 초저온 냉동보관 7일 후 이식, 그리고 4) 공여 토끼를 희생하지 않고 조직생검 기구를 이용하여 VX2 세포현탁액을 얻은 후 당일 이식하였다. 뇌 이식에는 정위 기구를 사용하였으며 하방 레버를 이용하여 5 mm 진입하여 VX2 세포 현탁액을 주입하였다. 10일 경과 후 MR imaging을 실시하였으며 다음 날 뇌 조직을 얻어 조직검사를 실시하여 MR 영상과 현미경 검사상 뇌종양의 생성 유무와 위치, 체적 등을 살펴보았다. 결과 VX2 세포 현탁액을 당일 이식한 토끼(n = 18)에서는 17마리(94.4%)에서 뇌종양이 생겼다(평균 체적은 106.32 mm³). 냉장 보관 후 7일에 세포 현탁액을 만들어 뇌 이식한 토끼(n = 5)에서는 1마리(20%)에서 뇌종양이 생겼으나 현미경으로만 확인되었다. 초저온 냉동 보관 후 7일에 세포 현탁액을 만들어 뇌 이식한 토끼는 5마리에서는 3마리(60%)에서 뇌종양이 생겼고 현미경으로만 확인되었다. 생검 횟수를 10회 실시한 후 이식한 3마리에서는 뇌종양이 생기지 않았고, 20회 실시한 후 이식한 2마리에서는 모두 뇌종양이 생겼으며 MR 영상과 조직검사에서 확인되었다(평균 체적 38.71 mm³). 네 가지 방법으로 발생한 종양의 위치는 superficial cortex가 대부분이었다. 결론 VX2 세포를 이식하여 토끼의 뇌종양 모델을 제작하는 기법은 쉽고 재현성은 다양했다. 이 모델은 뇌종양에 대한 영상, 치료 방법, 중재 시술 및 약물 전달 등 다양한 연구에 활용될 수 있을 것이다. 연구자의 처한 다양한 환경에 따라 다양한 방법으로 VX2 세포를 이식할 수 있을 것으로 생각된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권5호
• /
• pp.2539-2543
• /
• 2016

Background: In the Barcelona Clinic Liver Cancer (BCLC) system, only sorafenib is suggested for HCC patients having performance status (PS) 1 or 2 even if they have treatable lesions. In the current study, we aimed to explore the outcome of using aggressive treatment for HCC patients with PS 1 and 2. Materials and Methods: Five hundred and twenty four patients with HCC were enrolled in this study and divided into 2 groups: 404 PS 1 and 120 PS 2. Of the included 524 patients, 136 recceived non-aggressive supportive treatment and sorafenib, while 388 patients were offered aggressive treatment in the form of surgical resection, transplantation, percutaneous ablation, trans-arterial chemoembolization and/or chemoperfusion. All the patients were followed up for a period of 2 years to determine their survival. Results: Most HCC patients were CHILD A and B grades (89.4% versus 85.0%, for PS1 and PS2, respectively). Patients with PS1 were significantly younger. Out of the enrolled 524 patients, 388 were offered aggressive treatment, 253 (65.2%) having their lesions fully ablated, 94 (24.2%) undergoing partial ablation and 41 patients with no ablation (10.6%). The median survival of the patients with PS 1 who were offered aggressive treatment was 20 months versus 9 months only for those who were offered supportive treatment and sorafenib (p<0.001). Regarding HCC patients with PS 2, the median survivals were similarly 19.7 months versus 8.7 months only (p<0.001). Conclusions: Aggressive treatment of HCC patients with PS 1 and 2 significantly improves their survival. Revising the BCLC guidelines regarding such patients is recommended.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권9호
• /
• pp.4065-4069
• /
• 2015

Background: Epidermal growth factor-like domain multiple 7 (EGFL7), a secreted protein specifically expressed by endothelial cells during embryogenesis, recently was identified as a critical gene in tumor metastasis. Epithelial-mesenchymal transition (EMT) was found to be closely related with tumor progression. Accordingly, it is important to investigate the migration and EMT change after knock-down of EGFL7 gene expression in human pancreatic cancer cells. Materials and Methods: EGFL7 expression was firstly testified in 4 pancreatic cancer cell lines by real-time polymerase chain reaction (Real-time PCR) and western blot, and the highest expression of EGFL7 was found in PANC-1 cell line. Then, PANC-1 cells transfected with small interference RNA (siRNA) of EGFL7 using plasmid vector were named si-PANC-1, while transfected with negative control plasmid vector were called NC-PANC-1. Transwell assay was used to analyze the migration of PANC-1 cells. Real-time PCR and western blotting were used to detect the expression change of EGFL7 gene, EMT markers like E-Cadherin, N-Cadherin, Vimentin, Fibronectin and transcription factors like snail, slug in PANC-1, NCPANC-1, and si-PANC-1 cells, respectively. Results: After successful plasmid transfection, EGFL7 gene were dramatically knock-down by RNA interference in si-PANC-1 group. Meanwhile, migration ability decreased significantly, compared with PANC-1 and NC-PANC-1 group. Meanwhile, the expression of epithelial phenotype marker E-Cadherin increased and that of mesenchymal phenotype markers N-Cadherin, Vimentin, Fibronectin dramatically decreased in si-PANC-1 group, indicating a reversion of EMT. Also, transcription factors snail and slug decreased significantly after RNA interference. Conclusions: Current study suggested that highly-expressed EGFL7 promotes migration of PANC-1 cells and acts through transcription factors snail and slug to induce EMT, and further study is needed to confirm this issue.

• Journal of Chest Surgery
• /
• 제42권5호
• /
• pp.677-683
• /
• 2009

메이-터너 증후군은 좌측 장골정맥이 우측 총장골동맥에 눌러져 발생하는 장골-대퇴정맥의 심부정맥 혈전증이다. 비록 카테터를 이용한 혈전제거 술과 혈전용해 및 스텐트 삽입술이, 기술적 수월함과 낮은 재발율로 인해 급성기 혹은 아급성기의 메이-터너 증후군 환자들에게 보편적인 치료법으로 인식되고 있지만 일부 환자에서는 치명적인 합병증을 일으킬 수 있다. 더군다나 만성 메이-터너 증후군 환자에서의 궁극적인 적절한 치료법은 아직 정립되어 있지 않다. 저자들은 2예의 만성 메이-터너 증후군 환자에서 혈관 내 치료법 실패 후 수술적 혈전제거 술과 스텐트 삽관술, 동정맥루 조성술을 적용하였다. 이러한 수술적 치료법은 일부 혈관 내 치료가 적응증이 될 수 없는 환자에게 유의한 치료법으로 이용될 수 있을 것이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권7호
• /
• pp.3367-3371
• /
• 2012

Objective: To investigate the effects of histone deacetylase 6 (HDAC6) siRNA on cell proliferation and cell apoptosis of the HeLa cervical carcinoma cell line and the molecular mechanisms involved. Methods: Division was into three groups: A, the untreated group; B, the control siRNA group; and C, the HDAC6 siRNA group. Lipofectamine 2000 was used for siRNA transfection, and Western blot analysis was used to determine the protein levels. Cell proliferation and apoptosis were characterized using a CCK-8 assay and flow cytometry, respectively. Results: HDAC6 protein expression in the HDAC6 siRNA-transfection group was significantly lower (P < 0.05) than in the untreated and control siRNA groups. The CCK-8 kit results demonstrated that the proliferation of HeLa cells was clearly inhibited in the HDAC6 siRNA transfection group (P < 0.05). In addition, flow cytometry revealed that the early apoptotic rate ($26.0%{\pm}0.87%$) was significantly elevated (P < 0.05) as compared with the untreated group ($10.6%{\pm}1.19%$) and control siRNA group ($8.61%{\pm}0.98%$). Furthermore, Western blot analysis indicated that bcl-2 protein expression in the HDAC6 siRNA-transfection group was down-regulated, whereas the expression of p21 and bax was up-regulated. Conclusion: HDAC6 plays an essential role in the occurrence and development of cervical carcinoma, and the down-regulation of HDAC6 expression may be useful molecular therapeutic method.